Posts made in June 2018

Woman Running by Beach

Meet the Migraine Game-Changers

In this exclusive roundtable, Amgen/Novartis, Allergan, Lilly, and Teva recap the data that is moving their CGRP migraine preventives to the finish line.

Patients endure and manage around migraine disease. As such, people with migraine may feel as though time has been taken from them, or constantly live in anticipation of the next migraine attack. Compounding this effect, many migraine patients may not find the relief they need with existing treatment options, or cannot tolerant them.

Continue Reading Article

Hand Therapy

A New Frontier in Migraine Management

Inside CGRP Inhibitors & Migraine Prevention

With a series of calcitonin gene-related peptide antagonists that promise to prevent migraine now emerging from regulatory review, anticipation is growing across the healthcare and patient community. What can clinicians expect from this new class of monoclonal antibodies?

Calcitonin gene-related peptide (CGRP) is a vasoactive peptide. It is part of the “inflammatory soup” that is involved in dilation of cerebral and dural blood vessels. Widely distributed throughout the body, CGRP levels in serum increase during migraine or cluster headache. Triptans provide some migraine relief by modulating the CGRP.

Continue Reading Article

Foot Therapy

Efficacy of Pulsed Radiofrequency Stimulation in Patients

Pulsed radiofrequency stimulation (PRF) is increasingly being applied to alleviate several types of pain including neuralgia, joint pain, and muscle pain (1-5). This technique works by delivering an electrical field and heat bursts to targeted nerves or tissues via a catheter needle tip without damaging these structures (6-8). Conventional radiofrequency (CRF) thermocoagulation exposes target nerves or tissues to continuous electrical stimulation and ablates the structures by increasing the temperature around the tip of the RF needle (9). In contrast to CRF, PRF applies a brief electrical stimulation, followed by a long resting phase; thus, PRF does not produce sufficient heat to cause structural damage (10). During the PRF procedure, the catheter needle tip is placed near the targeted nerves, and then advanced towards the nerves until patients report a tingling sensation and/or dysesthesia at a voltage less than 0.2 to 0.5 V. The tissue temperature is maintained at or below 42°C on average.

Continue Reading Article